6612 Stock Overview
ICARES Medicus, Inc., a nano-medical material company, focuses on the research and development, manufacture, and sale of ophthalmic medical materials in Taiwan and internationally.
ICARES Medicus Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$84.80|
|52 Week High||NT$103.00|
|52 Week Low||NT$59.00|
|1 Month Change||3.04%|
|3 Month Change||6.00%|
|1 Year Change||32.71%|
|3 Year Change||24.71%|
|5 Year Change||68.92%|
|Change since IPO||67.92%|
Recent News & Updates
|6612||TW Medical Equipment||TW Market|
Return vs Industry: 6612 exceeded the TW Medical Equipment industry which returned -12.4% over the past year.
Return vs Market: 6612 exceeded the TW Market which returned -19.9% over the past year.
|6612 Average Weekly Movement||5.4%|
|Medical Equipment Industry Average Movement||5.5%|
|Market Average Movement||5.0%|
|10% most volatile stocks in TW Market||8.2%|
|10% least volatile stocks in TW Market||2.4%|
Stable Share Price: 6612 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 6612's weekly volatility (5%) has been stable over the past year.
About the Company
ICARES Medicus, Inc., a nano-medical material company, focuses on the research and development, manufacture, and sale of ophthalmic medical materials in Taiwan and internationally. It provides ophthalmic medical materials, including intraocular lens for the treatment of cataract, myopia, hyperopia, presbyopia, or astigmatism; and surgical implantation systems, as well as related technical services. The company was incorporated in 2011 and is based in Zhubei, Taiwan.
ICARES Medicus Fundamentals Summary
|6612 fundamental statistics|
Is 6612 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6612 income statement (TTM)|
|Cost of Revenue||NT$85.52m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||2.95|
|Net Profit Margin||22.04%|
How did 6612 perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is 6612 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6612?
Other financial metrics that can be useful for relative valuation.
|What is 6612's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 6612's PE Ratio compare to its peers?
|6612 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
1786 SciVision Biotech
4129 United Orthopedic
4155 OK Biotech
4126 Pacific Hospital Supply
6612 ICARES Medicus
Price-To-Earnings vs Peers: 6612 is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the peer average (21.5x).
Price to Earnings Ratio vs Industry
How does 6612's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
Price-To-Earnings vs Industry: 6612 is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the TW Medical Equipment industry average (18.8x)
Price to Earnings Ratio vs Fair Ratio
What is 6612's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||28.7x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6612's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 6612 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6612 (NT$84.8) is trading above our estimate of fair value (NT$11.23)
Significantly Below Fair Value: 6612 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is ICARES Medicus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ICARES Medicus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Check out ICARES Medicus's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
How has ICARES Medicus performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6612 has high quality earnings.
Growing Profit Margin: 6612's current net profit margins (22%) are higher than last year (10.6%).
Past Earnings Growth Analysis
Earnings Trend: 6612's earnings have grown by 9.4% per year over the past 5 years.
Accelerating Growth: 6612's earnings growth over the past year (176.5%) exceeds its 5-year average (9.4% per year).
Earnings vs Industry: 6612 earnings growth over the past year (176.5%) exceeded the Medical Equipment industry 19%.
Return on Equity
High ROE: 6612's Return on Equity (9.6%) is considered low.
Discover strong past performing companies
How is ICARES Medicus's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 6612's short term assets (NT$572.8M) exceed its short term liabilities (NT$148.1M).
Long Term Liabilities: 6612's short term assets (NT$572.8M) exceed its long term liabilities (NT$16.6M).
Debt to Equity History and Analysis
Debt Level: 6612 has more cash than its total debt.
Reducing Debt: 6612's debt to equity ratio has reduced from 19.9% to 0.4% over the past 5 years.
Debt Coverage: 6612's debt is well covered by operating cash flow (2536.1%).
Interest Coverage: 6612 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is ICARES Medicus's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|ICARES Medicus Dividend Yield vs Market|
|Company (ICARES Medicus)||0.6%|
|Market Bottom 25% (TW)||2.5%|
|Market Top 25% (TW)||7.0%|
|Industry Average (Medical Equipment)||3.9%|
|Analyst forecast in 3 Years (ICARES Medicus)||n/a|
Notable Dividend: 6612's dividend (0.59%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.54%).
High Dividend: 6612's dividend (0.59%) is low compared to the top 25% of dividend payers in the TW market (6.96%).
Stability and Growth of Payments
Stable Dividend: 6612 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.
Growing Dividend: 6612 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 6612 is not paying a notable dividend for the TW market.
Cash Payout to Shareholders
Cash Flow Coverage: 6612 is not paying a notable dividend for the TW market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Ih-Houng Loh serves as Chairman of the Board and Chief Executive Officer since December 7, 2016 of ICARES Medicus, Inc. and has been its Director since July 14, 2011. Mr. Loh serves as Chairman of the...
Experienced Management: 6612's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: 6612's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
ICARES Medicus, Inc.'s employee growth, exchange listings and data sources
- Name: ICARES Medicus, Inc.
- Ticker: 6612
- Exchange: TPEX
- Founded: 2011
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: NT$2.897b
- Shares outstanding: 34.16m
- Website: https://www.icaresmedicus.com
Number of Employees
- ICARES Medicus, Inc.
- No. 16, Shengyi Road
- 4th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6612||TPEX (Taipei Exchange)||Yes||Ordinary Shares||TW||TWD||Dec 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/27 00:00|
|End of Day Share Price||2022/09/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.